- Home
- ACET vs NPT Comparison
ACET vs NPT Comparison
Compare ACET & NPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- NPT
- Stock Information
- Founded
- ACET 1947
- NPT 2011
- Country
- ACET United States
- NPT China
- Employees
- ACET N/A
- NPT N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- NPT Specialty Chemicals
- Sector
- ACET Health Care
- NPT Consumer Discretionary
- Exchange
- ACET Nasdaq
- NPT Nasdaq
- Market Cap
- ACET 111.9M
- NPT 113.1M
- IPO Year
- ACET N/A
- NPT 2025
- Fundamental
- Price
- ACET $0.64
- NPT $4.34
- Analyst Decision
- ACET Buy
- NPT
- Analyst Count
- ACET 4
- NPT 0
- Target Price
- ACET $8.50
- NPT N/A
- AVG Volume (30 Days)
- ACET 2.2M
- NPT 308.8K
- Earning Date
- ACET 11-05-2025
- NPT 11-23-2025
- Dividend Yield
- ACET N/A
- NPT N/A
- EPS Growth
- ACET N/A
- NPT N/A
- EPS
- ACET N/A
- NPT 0.03
- Revenue
- ACET N/A
- NPT $857,425,672.00
- Revenue This Year
- ACET N/A
- NPT N/A
- Revenue Next Year
- ACET N/A
- NPT N/A
- P/E Ratio
- ACET N/A
- NPT $117.71
- Revenue Growth
- ACET N/A
- NPT 25.23
- 52 Week Low
- ACET $0.45
- NPT $3.58
- 52 Week High
- ACET $1.40
- NPT $9.18
- Technical
- Relative Strength Index (RSI)
- ACET 31.44
- NPT N/A
- Support Level
- ACET $0.66
- NPT N/A
- Resistance Level
- ACET $0.71
- NPT N/A
- Average True Range (ATR)
- ACET 0.07
- NPT 0.00
- MACD
- ACET -0.03
- NPT 0.00
- Stochastic Oscillator
- ACET 7.83
- NPT 0.00
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.